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OBJECTIVES: To evaluate the cost effectiveness of vildagliptin compared to pioglita-
zone and glimepiridewhen added on tometformin in the treatment of type 2 diabetes
mellitus inChina.METHODS:AMarkovmodelwasdesigned to evaluate the costs and
outcomes (life years and QALYs gained) of three different therapies of diabetesmelli-
tus from health insurance perspective. Based on UKPDS Outcomes Model, the model
included the following riskengine tosimulatecomplications, including ischemicheart
disease, fatal and non-fatal myocardial infarction, heart failure, stroke, blindness,
renal failure, amputation, diabetes-related mortality and other deaths. The clinical
and quality of life data were obtained from published literature and re-confirmed
based on a questionnaire survey froma clinical expert panel of 20 diabetes specialists.
The annual cost was calculated based on expert opinions. A probabilistic sensitivity
analysis was performed to understand the key drivers and general sensitivity of the
model. RESULTS: The results showed that compared to the treatment of
metforminpioglitazone and metforminglimepiride therapy, the add-on of vilda-
gliptin canprovide a gain of 0.07 and 0.13QALYsper patient, respectively. The lifetime
cost per patient treated with vildagliptin, pioglitazone and glimepiride added-on to
metformin was CNY 124,892 (US$19,824), CNY 134,135 (US$21,291) and CNY 126,010
(US$20,002), respectively.CONCLUSIONS: Compared tometforminpioglitazone and
metforminglimepiride therapies, vildagliptin add-on to metformin therapy im-
proves health outcomes and also leads to cost saving in the treatment of diabetes
mellitus in China.
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COST-EFFECTIVENESS MODELLING OF TYPE-1 DIABETES
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OBJECTIVES: To build a flexible and comprehensive long term Type-1 diabetes
model incorporating themost up-to-date methodologies (e.g. capturing parameter
uncertainty, timeprofile of patient characteristics and including patient behaviour)
to allow a number of cost-effectiveness evaluations.METHODS: An individual pa-
tient level discrete event simulationmodel which includes all the major complica-
tions (nephropathy, neuropathy, retinopathy, CVD, PVD, hypoglycaemia, ketoaci-
dosis) and their interactions along with the treatment effects was built based on
the developed conceptual model. Patient characteristics (demographics, clinical
variables, existing complications and treatment status) are used to estimate the
transition probabilities for different eventswithHbA1c acting as the key variable in
themodel. Patient behaviourwas also incorporated in the cost-effectivenessmodel
by updating HbA1c and other variables in time based on the patient’s behaviour.
The model was developed in a flexible manner to allow alternative sets of risk
equations to be used and themodel is being validated for each set of risk equations.
Furthermore, the model is capable of performing probabilistic sensitivity analysis
allowing us to capture the effects of parameter uncertainty and report the likeli-
hood that interventions are cost-effective. RESULTS: A number of cost-effective
analyses were performed and the trade-offs between costs and QALYs are pre-
sented for different treatment/interventions. CONCLUSIONS: The flexible individ-
ual patient level discrete event simulationmodel developed enables cost-effective-
ness evaluations of a number of treatments and interventions for Type-1 diabetes.
The model allows tracking the history of each of the patients and this enables
identification of different sub-groups for targeted interventions. Sensitivity analy-
sis, probabilistic sensitivity analysis and value of informationmethodswill be used
to identify the most important parameters in the model.
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OBJECTIVES: Although hypertension and obesity are common comorbidities among
patients with type 2 diabetes (T2D), their prevalence and burden has often not been
explored outside the US. The objective of the current study was to assess the incre-
mental effect of eachcomorbidity in isolationand in combinationamongT2Dpatients
in Japan.METHODS: Data from the 2010 Japan National Health andWellness Survey
(NHWS) were used in the analysis. The NHWS is an Internet-based self-reported sur-
vey administered to the adult population of Japan (N25,000). Respondents who re-
ported a diagnosis of T2D and provided weight information were included in the
analysis; they were subsequently categorized based on their comorbidities:
T2Dobesityonly,T2Dhypertensiononly,T2Dobesityhypertension,orT2Dwith-
out either obesity or hypertension. Groupswere compared on health status (using the
SF-12v2) and self-reported health care resource use in the past six months through
regression modeling controlling for demographics, health behaviors, and
comorbidities. RESULTS: Of the 957 patients who reported a diagnosis of T2D, most
reported neither an obesity nor hypertension comorbidity (n506; 52.87%). 255
(26.65%) patients reported T2Dhypertension, 98 (10.24%) reported T2Dobesity, and
98 (10.24%) reported both T2Dhypertensionobesity. Adjusting for demographics,
health behaviors, and comorbidities, patients with T2Dobesity (Mean43.42),
T2Dhypertension (Mean46.51), and T2Dobesityhypertension (Mean44.03) all
reported significantly worse physical component summary scores than those with
only T2D (Mean47.76) (p.05). Similar, though slightly weaker, differences were ob-
served with respect to health utilities. All comorbidity groups also reported signifi-
cantly more physician visits (T2Dobesity14.25; T2Dhypertension12.06;
T2Dhypertensionobesity15.37) in the past sixmonths comparedwith thosewith
only T2D (9.94; all ps.05).CONCLUSIONS:Althoughmost patients in Japanwith T2D
do not have concomitant hypertension or obesity, those that do report a significant
health status and direct cost burden. Improved management of these comorbidities
could result in a substantial societal benefit.
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OBJECTIVES: Past research has shown strong associations of hypertension and obe-
sitywith type2diabetes (T2D); however,most of these studieshavebeenconducted in
the US. Given that 92million patients in China currently have diabetes, the aim of the
current study was to assess the prevalence and burden associated with these two
comorbidities.METHODS: The data source for the current study was the 2010 China
National Health and Wellness Survey (NHWS). The NHWS is a self-reported survey
administered to the adult population of urban China using a mixed methodology
(N19,954). Only respondents who reported that they had been diagnosed with T2D,
and who provided weight information, were included in the analysis. Those with
T2Dhypertension only, T2Dobesity only, and T2Dobesityhypertension were
compared with T2D only patients on health status (using the SF-12v2) and self-re-
ported health care resource use in the past six months. Regression modeling con-
trolled for demographics, health behaviors, and comorbidities. RESULTS: A total of
552 patients reported a diagnosis of type 2 diabetes with 148 (26.81%) reporting con-
comitant hypertension, 52 (9.42%) being obese, 43 (7.79%) reporting hypertension and
being obese, and 309 (55.98%) having neither comorbidity. Adjusting for demograph-
ics, health behaviors, and comorbidities, patients with T2Dhypertension
(Mean42.25), T2Dobesity (Mean42.29) and T2Dobesityhypertension
(Mean40.99) all reported significantly worse physical component summary scores
than those with only T2D (Mean44.80) (p.05). All comorbidity groups also reported
significantly worse health utilities (T2Dhypertension0.67; T2Dobesity0.67;
T2Dhypertensionobesity0.67) compared with those with only T2D (0.71). Similar
significant effects were observed for the number of provider visits, emergency room
visits, and hospitalizations. CONCLUSIONS: Although most patients in urban China
with T2D do not have concomitant hypertension or obesity, those that do report a
significant health status and direct cost burden. Improved management of T2D and
these comorbidities could result in a large societal benefit.
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OBJECTIVES: A recent study showed that 4mm pen needle (PN) has significantly
lowered risk of intramuscular insulin injection and thus reduced risk of hypogly-
cemia. It is important, however, to understand whether diabetes patients are well
adapted to 4mm PN when switched from longer needles. The study is to evaluate
the difference in patient perception and outcomes before and after switching to the
new 4mm PN. METHODS: A prospective pilot survey study was conducted from
August 2011 to March 2012 in two public hospitals in Hong Kong. Thirty-four sub-
jects with diabetes on longer PN (8mm, 6mm or 5mm) were randomly selected and
consented to switch to 4mm PN for two to four weeks. Questionnaires included
perception and outcomes Five-point Likert scales were employed to measure pain
level, satisfaction level, insulin leakage, injection pressure, and ease of injection to
different body areas pre- and post- switch of longer to shorter PN. Insulin leakage
volume pre- and post switch was compared using a droplet size chart representing
1uL, 10uL, 20uL, and 40uL. Statistical analyses were conducted using SAS (v9.1).
RESULTS: The overall response rate was 94.1% (N32). Demographics of respon-
dents: 48.918.6 years (13-76 years); 64.5% females; 46.7% T1DM; A1C: 8.71.7%
(5.7-12.7%); BMI: 24.045.1kg/ m2 (17.5-40.0kg/m2); average insulin dosage:
46.918.6U (6-86U). Of all analyzed, 33.3% generally injected with high speed to
avoid pain. There was no significant difference in the volume of insulin leakage
pre- and post PN switch when injecting on abdomen (p 0.7530) or thigh
(p0.5637); no significant difference in level of pain (p0.0519). CONCLUSIONS:
The use of 4mm PN showed no difference in outcomes and perception of use when
switched from 8, 6, 5 mm PN in a heterogeneous sample with obese, overweight,
normal and skinny patients. A tendency of preference towards 4mmPNwith lower
pain level and less leakage may be observed with larger sample size.
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PHYSICIAN’S AND PATIENT’S PERCEPTIONS AND BELIEFS REGARDING INSULIN
INITIATION AND USE IN PATIENTS WITH TYPE 2 DIABETES (T2DM) IN CHINA
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OBJECTIVES: To explore physician’s and patient’s perceptions of insulin initiation
and use in patients with T2DM in China. METHODS: This study used the 2008
Adelphi T2DM Disease Specific Programme©, a cross-sectional study of consulting
physicians and patients providing insights into ‘real-world’ behaviours and atti-
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